Clinical trials: Basal-Like Breast Carcinoma
Breast Neoplasm
Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
The primary objective of this study is to determine whether overall response to cetuximab combined with cisplatin is better than overall response to cisplatin alone together with showing that the overall response for cetuximab…
- Trial name
- BALI-1 (NCT00463788)
- Testing
- cetuximab, cisplatin, cisplatin
- Where
- 46 sites in Australia, Austria and 9 more
- Volunteers
- 181 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Solid Tumors
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
This is a two-part trial in patients with squamous non-small cell lung cancer (NSCLC), platinum (Pt)-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer (TNBC).
- Trial name
- NCT01930292
- Testing
- Part A: Debio 1143, Paclitaxel, Carboplatin
- Where
- 4 sites in France
- Volunteers
- 31 people
- Sponsor
- Debiopharm International SA
Breast Tumor, Breast Cancer
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects…
- Conditions
- Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer
- Trial name
- tnAcity (NCT01881230)
- Testing
- nab-Paclitaxel, Carboplatin, Gemcitabine
- Where
- 140 sites in United States, Australia and 10 more
- Volunteers
- 191 people
- Sponsor
- Celgene